<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990495</url>
  </required_header>
  <id_info>
    <org_study_id>E0915-R</org_study_id>
    <nct_id>NCT01990495</nct_id>
  </id_info>
  <brief_title>Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of individuals with advanced ESRD have reduced exercise capacity in part due to&#xD;
      decreased muscle mass. This leads to a reduced ability to perform daily activities, a greater&#xD;
      incidence of falls, and a reduced quality of life. The mechanisms responsible for the loss of&#xD;
      muscle mass in ESRD are not understood very well. This study is designed to determine the&#xD;
      effectiveness of an exercise program on improving muscle mass, exercise capacity and quality&#xD;
      of life in persons with ESRD. In addition, the study will attempt to better understand why&#xD;
      muscle loss occurs in people with ESRD, the influence exercise has on these mechanisms, and&#xD;
      whether the response to exercise can be enhanced with nutrient supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly patients comprising half the end-stage renal disease (ESRD) population, are&#xD;
      especially vulnerable to loss of muscle mass, strength and function, changes that lead to&#xD;
      frailty and increased morbidity and mortality. Many factors contribute to the decline in&#xD;
      muscle mass and function in the elderly uremic and apart from aging and co-morbid conditions,&#xD;
      wasting is worsened by inactivity. Studies in maintenance hemodialysis (MHD) patients have&#xD;
      shown that exercise (EX), including endurance, resistance or combined, can counteract the&#xD;
      loss of muscle mass and function. However most studies have not specifically targeted the&#xD;
      elderly, involved small numbers or lacked controls and the impact on long-term outcome is&#xD;
      unknown. Nevertheless, despite substantial evidence indicating that EX is beneficial and low&#xD;
      cost, EX is not part of the routine care of MHD patients. In contrast EX is regarded as&#xD;
      standard of care for the wasted elderly and also cardiac patients. Some protection against&#xD;
      uremic muscle wasting can also be afforded by an adequate protein-calorie intake. Amino acids&#xD;
      (AA) from this source serve as substrates for protein synthesis (PS) and also directly&#xD;
      activate the mTOR signaling pathway stimulating PS. In normal subjects if AA are ingested at&#xD;
      the time of resistance EX, anabolic signaling and PS is enhanced and this leads to increases&#xD;
      in muscle mass. Whether the EX and AA stimulated signaling response is intact in elderly MHD&#xD;
      patients is unknown and there is little information about the cellular processes invoked.&#xD;
      Taking this all together, the investigators plan to test the hypothesis that a home-based EX&#xD;
      program, effective in cardiac patients, will improve cardiopulmonary function and muscle mass&#xD;
      and function in elderly MHD patients. Also, in a pilot study the investigators will examine&#xD;
      whether a protein supplement acutely enhances EX stimulated anabolic signaling. Functionally&#xD;
      impaired MHD subjects aged 65-80 yrs are randomized into 2 groups of 30 each, one undergoing&#xD;
      EX and the other usual care. After 3 months, half in each group receive a one-time&#xD;
      protein-calorie supplement or placebo during an acute bout of EX and muscle biopsied for&#xD;
      examining the signaling response. Assays at baseline and at 3 months include cardiopulmonary&#xD;
      function, muscle strength and function, body composition by DEXA, thigh muscle volume and&#xD;
      composition by CT, quality of life (QOL) and cognitive function, and nutritional,&#xD;
      inflammatory, lipid and biochemical status and morphologic and molecular analysis of biopsied&#xD;
      muscle. The investigators anticipate that home-based EX will counteract muscle wasting,&#xD;
      enhance cardiopulmonary and muscle function and QOL, and reduce surrogate markers of&#xD;
      long-term outcome. New insights into the mechanisms whereby EX and nutrients induce an&#xD;
      anabolic response in muscle of elderly uremics will be provided and may serve as a basis for&#xD;
      devising strategies to counteract loss of muscle mass and function. Finally, the&#xD;
      investigators anticipate that the EX program will be &quot;user friendly&quot; and may thus form a part&#xD;
      of the routine care of elderly and perhaps younger MHD patients. If short-term benefits are&#xD;
      evident from this study in elderly MHD patients, it could form the basis for a comprehensive&#xD;
      long-term outcomes study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2013</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Oxygen Uptake</measure>
    <time_frame>3 months</time_frame>
    <description>The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy of the Quadriceps Muscle.</measure>
    <time_frame>3 Months</time_frame>
    <description>The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle.&#xD;
The biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>3 months</time_frame>
    <description>Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function.&#xD;
Higher scores mean better values using a 0-100 scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Exercise vs. usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study involves two arms randomized to exercise and usual care groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>Subjects will participate in a center-based and home exercise training program for 3 months.</description>
    <arm_group_label>Exercise vs. usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>This group will serve as control subjects. They will receive only usual clinical care.</description>
    <arm_group_label>Exercise vs. usual care</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 55-80 years undergoing maintenance hemodialysis (MHD) for at&#xD;
             least three months and without other active/uncontrolled disease will be studied.&#xD;
&#xD;
          -  Exercise and usual care groups will be matched by age, body mass index (BMI), MHD&#xD;
             duration, and protein intake using a stratified randomization approach.&#xD;
&#xD;
          -  Subjects will be required to be in the peak VO2 range of 10 to 20 ml/kg/min,&#xD;
             equivalent to moderate functional impairment in patients with heart failure.&#xD;
&#xD;
          -  Subjects will be required to have dialysis treatment for &gt;3 months with an average&#xD;
             Kt/V 1.2, and be able to perform exercise safely.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current activity &gt; 2 hrs/wk of moderate intensity exercise, temporary vascular access,&#xD;
             uncontrolled diabetes mellitus, active vasculitis, active autoimmune disease,&#xD;
             malignancy, severe obesity (BMI &gt; 35), alcoholism or other recreational drug use,&#xD;
             unstable cardiac disease (abnormal exercise test, angina, uncontrolled arrhythmias or&#xD;
             myocardial infarction within three months), peripheral vascular disease (claudication&#xD;
             with exercise), lung, liver or intestinal disease, those who are medically unstable&#xD;
             and subjects who have received anabolic, catabolic or cytotoxic medications in the&#xD;
             past 3 months.&#xD;
&#xD;
          -  The investigators will also exclude subjects with excessive previous exposure to&#xD;
             radiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Neil Myers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System, Palo Alto, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>December 3, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal failure</keyword>
  <keyword>Exercise testing</keyword>
  <keyword>Exercise training</keyword>
  <keyword>Protein signaling</keyword>
  <keyword>Skeletal muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT01990495/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exercise</title>
          <description>The study involves two arms randomized to exercise and usual care groups&#xD;
Exercise training: Subjects will participate in a center-based and home exercise training program for 3 months.&#xD;
Usual Care: This group will serve as control subjects. They will receive only usual clinical care.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.&#xD;
Usual Care: This group will serve as control subjects. They will receive only usual clinical care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Chronic kidney disease on maintenance hemodialysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Exercise</title>
          <description>Subjects will participate in a center-based and home exercise training program for 3 months.</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.6"/>
                    <measurement group_id="B2" value="66.2" spread="6.7"/>
                    <measurement group_id="B3" value="66.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Oxygen Uptake</title>
        <description>The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.</description>
        <time_frame>3 months</time_frame>
        <population>Chronic kidney disease</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>Subjects will participate in a center-based and home exercise training program for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Oxygen Uptake</title>
          <description>The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.</description>
          <population>Chronic kidney disease</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="3.3"/>
                    <measurement group_id="O2" value="15.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy of the Quadriceps Muscle.</title>
        <description>The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle.&#xD;
The biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.</description>
        <time_frame>3 Months</time_frame>
        <population>Maintenance hemodialysis (&gt;3 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>Subjects will participate in a hybrid, center-based and home exercise training program for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>This group will serve as control subjects. They will receive only usual clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy of the Quadriceps Muscle.</title>
          <description>The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle.&#xD;
The biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.</description>
          <population>Maintenance hemodialysis (&gt;3 months)</population>
          <units>Percentage of type 1 fibers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="11"/>
                    <measurement group_id="O2" value="30.0" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Score</title>
        <description>Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function.&#xD;
Higher scores mean better values using a 0-100 scale.</description>
        <time_frame>3 months</time_frame>
        <population>Chronic kidney disease on maintenance hemodialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise</title>
            <description>Subjects will participate in a center-based and home exercise training program for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>This group will serve as control subjects. They will receive only usual clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Score</title>
          <description>Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function.&#xD;
Higher scores mean better values using a 0-100 scale.</description>
          <population>Chronic kidney disease on maintenance hemodialysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="25.6"/>
                    <measurement group_id="O2" value="60.0" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Subjects were monitored for any adverse events related to exercise testing, training, blood draws, and biopsy procedures. There were no adverse events during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Exercise</title>
          <description>Subjects will participate in a center-based and home exercise training program for 3 months.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jonathan Myers</name_or_title>
      <organization>VA Palo Alto Health Care System</organization>
      <phone>6504503440</phone>
      <email>Drj993@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

